Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 피인용
- Web of Science 16
- JCR IF
- JCR 2015 2.134
- ISSN
- 2314-6133
저자
- Han, Kyoung Hee제1저자제주대학교, Sch Med, Dept Pediat, KO
- 김성헌교신저자부산대병원, 부산대학교병원, 대학병원, 20 Geumo Ro, KO
초록
Focal segmental glomerulosclerosis (FSGS) is a nephrotic syndrome. Up to around 80% of cases of primary FSGS are resistant to steroid treatment. A large proportion of patients with steroid-resistant FSGS progress to end-stage renal disease. The purpose of treatment is to obtain a complete remission of proteinuria, a necessary step that precedes improved renal survival and reduces the risk of progression to chronic kidney disease. When this is not possible, the secondary goal is a partial remission of proteinuria. Reduction or remission of proteinuria is the most important factor predictive of renal survival. We will review the current updated strategies for treatment of primary FSGS in children, including traditional therapies consisting of corticosteroids and calcineurin inhibitors and novel therapies such as rituximab, abatacept, adalimumab, and fresolimumab.
키워드
RESISTANT NEPHROTIC SYNDROMEADRENOCORTICOTROPIC HORMONE GELORAL GALACTOSE THERAPYPULSE CYCLOPHOSPHAMIDEIDIOPATHIC NEPHROSISPERMEABILITY FACTORINITIAL THERAPYKIDNEY-DISEASECYCLOSPORINELONG
식별자
- WoS UID
- 000375320100001



로그인
연구물 목록으로